NASDAQ$VRCA
Verrica Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Verrica reported a net loss for Q3 2021, but made progress with VP-102 and LTX-315.
Verrica Pharmaceuticals reported a net loss of $12.8 million for the third quarter of 2021. The company is engaging with the FDA on next steps toward potential approval of VP-102 for the treatment of molluscum contagiosum and expects to initiate a Phase 2 trial in basal cell carcinoma in the first quarter of 2022 for LTX-315.
- FDA issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 due to deficiencies at a contract manufacturing organization (CMO).
- The CMO's inspection has been classified as "voluntary action indicated" (VAI), is now closed and that the VAI classification will not directly negatively impact FDA’s assessment of the Company’s NDA regarding this CMO.
- Submitted an Investigational New Drug Application (IND) for LTX-315 for use in basal cell carcinoma.
- Expects to initiate Phase 2 trial in basal cell carcinoma in the first quarter of 2022.
Headline financials
Revenue & EPS history
Verrica · Revenue · Quarterly
$12M
Forward guidance
Verrica believes that its existing cash, cash equivalents, and marketable securities as of September 30, 2021 will be sufficient to support planned operations into the third quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-1.1%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+18.6%
Q1 2024
Best reaction
-47.9%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -15.3% | -19.9% | |
| Q4 2025 | +4.7% | +3.2% | -14.5% | |
| Q3 2025 | +3.2% | +15.8% | +104.7% | |
| Q1 2025 | +2.9% | -0.8% | -3.0% | |
| Q4 2024 | -7.6% | +0.5% | -25.3% | |
| Q3 2024 | -47.9% | -45.8% | -22.2% | |
| Q2 2024 | -44.8% | -43.8% | -62.6% | |
| Q1 2024 | +18.6% | +8.4% | +7.3% | |
| Q4 2023 | -3.0% | -10.1% | +3.5% | |
| Q3 2023 | -13.6% | -17.7% | +7.6% | |
| Q2 2023 | +7.6% | +1.6% | -18.5% | |
| Q1 2023 | -1.4% | -7.1% | -13.9% | |
| Q4 2022 | -6.9% | +1.5% | -21.6% | |
| Q3 2022 | -3.1% | +3.1% | +43.7% | |
| Q2 2022 | +17.1% | +9.6% | +18.8% | |
| Q1 2022 | -1.6% | -7.8% | -63.0% | |
| Q4 2021 | +1.3% | -7.7% | +1.9% | |
| Q3 2021 | -4.2% | -5.9% | -22.2% | |
| Q2 2021 | -1.6% | -0.7% | +12.6% | |
| Q1 2021 | -0.8% | -0.2% | -14.8% | |
| Q4 2020 | -9.6% | -0.2% | +1.3% | |
| Q3 2020 | +13.9% | +13.1% | +32.3% | |
| Q2 2020 | +5.6% | +4.8% | +29.6% | |
| Q1 2020 | +10.5% | +2.8% | +24.0% | |
| Q4 2019 | -12.1% | -7.5% | +31.3% | |
| Q3 2019 | +0.8% | +4.0% | -7.3% | |
| Q2 2019 | +2.6% | -9.3% | -2.3% | |
| Q1 2019 | +1.0% | -3.3% | -23.4% | |
| Q4 2018 | -7.5% | +1.1% | -8.0% | |
| Q3 2018 | -3.8% | +5.6% | -22.7% | |
| Q2 2018 | -0.9% | +2.7% | +13.8% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro